MS049 is a potent and selective inhibitor of the epigenetic reader protein BRD9, which plays a role in chromatin remodeling and gene regulation. It is primarily used in research settings to study the biological functions of BRD9 within the SWI/SNF chromatin-modifying complex. By selectively targeting BRD9, MS049 allows scientists to probe the role of this protein in various cellular processes, including transcriptional regulation, cell differentiation, and proliferation. The compound has been instrumental in studies exploring the therapeutic potential of BRD9 inhibition in cancer, particularly in models of acute myeloid leukemia and other malignancies dependent on aberrant chromatin regulation. Its selectivity makes it a valuable tool for distinguishing BRD9-specific effects from those of related proteins such as BRD7 or other bromodomain-containing factors. In addition to oncology research, MS049 is used to investigate inflammatory and immune responses, as BRD9 has been implicated in the regulation of key immune signaling pathways. The compound enables target validation in cellular and biochemical assays, supporting the development of novel epigenetic therapies. Due to its research-focused utility, MS049 is widely applied in pharmacological and mechanistic studies in academic and pharmaceutical laboratories.